News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
491,095 Results
Type
Article (36291)
Company Profile (141)
Press Release (454663)
Section
Business (149506)
Career Advice (1525)
Deals (28838)
Drug Delivery (90)
Drug Development (69272)
Employer Resources (123)
FDA (11630)
Job Trends (11297)
News (266407)
Policy (29328)
Tag
Academia (1943)
Africa (686)
Alliances (46184)
Alzheimer's disease (984)
Antibody-drug conjugate (ADC) (47)
Approvals (11578)
Arizona (77)
Artificial intelligence (58)
Asia (32769)
Australia (5232)
Bankruptcy (265)
Best Places to Work (8478)
Biosimilars (52)
Biotechnology (69)
C2C Services and Suppliers (36558)
California (1082)
Canada (647)
Cancer (274)
Career advice (1277)
Cell therapy (83)
China (90)
Clinical research (54198)
Collaboration (99)
Colorado (47)
COVID-19 (2429)
Cystic fibrosis (46)
Data (100)
Diabetes (56)
Diagnostics (3785)
Drug pricing (67)
Earnings (53097)
Employer resources (107)
Europe (72402)
Events (64668)
Executive appointments (65)
FDA (11749)
Florida (132)
Funding (61)
Gene therapy (71)
GLP-1 (526)
Government (4174)
Healthcare (12408)
Hotbed/Location (327713)
Illinois (145)
Indiana (98)
Infectious disease (2456)
Inflammatory bowel disease (76)
Interviews (262)
IPO (12141)
Job creations (2893)
Job search strategy (1119)
Kansas (67)
Layoffs (305)
Legal (7747)
Liver cancer (43)
Lung cancer (57)
Manufacturing (76)
Maryland (261)
Massachusetts (884)
Medical device (6378)
Medtech (6380)
Mergers & acquisitions (16558)
Metabolic disorders (221)
Michigan (53)
Minnesota (77)
Neuroscience (1080)
New Jersey (351)
New York (358)
NextGen Class of 2024 (4255)
Non-profit (2957)
North Carolina (380)
Northern California (510)
Obesity (141)
Ohio (66)
Opinion (184)
Patents (51)
Pennsylvania (342)
People (39811)
Pharmaceutical (62)
Phase I (16053)
Phase II (23633)
Phase III (18869)
Pipeline (79)
Policy (53)
Postmarket research (2218)
Preclinical (6756)
Rare diseases (81)
Real estate (4063)
Recruiting (51)
Regulatory (18238)
Research institute (1796)
Resumes & cover letters (224)
South America (987)
Southern California (461)
Startups (2637)
Texas (112)
United States (4906)
Vaccines (492)
Washington State (143)
Weight loss (134)
Date
Last 7 days (330)
Last 30 days (1660)
Last 365 days (28055)
2024 (18424)
2023 (29742)
2022 (39221)
2021 (42080)
2020 (40259)
2019 (33347)
2018 (25549)
2017 (25255)
2016 (24090)
2015 (27823)
2014 (22008)
2013 (18297)
2012 (19516)
2011 (20307)
2010 (18643)
491,095 Results for "neovii pharmaceuticals ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Business
Neovii and Fosun Pharma Enter Into an Exclusive Agreement
Neovii Pharmaceuticals AG and Shanghai Fosun Pharmaceutical Industry Development Co. Ltd have entered into an exclusive agreement, under which Neovii has granted Fosun Pharma Industry an exclusive license to develop and commercialize Neovii’s Grafalon® in Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region.
September 7, 2022
·
6 min read
Biotech Bay
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
Mirum Pharmaceuticals, Inc. has adopted a positive opinion of LIVMARLI® (maralixibat) oral solution for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients three months of age and older.
May 31, 2024
·
8 min read
BioCapital
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal
Telomir Pharmaceuticals, Inc. announced that Michael F. Roizen, MD, a leader in age-related medicine and an existing advisor to the Company, will be increasing his role in the coming months as a Special Advisor on Age Reversal.
March 5, 2024
·
5 min read
Business
Alamar Biosciences and Biomarkers of Aging Consortium Join Forces to Revolutionize Longevity Research
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease in collaboration with the Biomarkers of Aging Consortium announced the launch of the next phase of the Biomarkers of Aging Challenge Series.
June 27, 2024
·
3 min read
GlycoProteMim Featured in Stonegate Healthcare’s Latest Anti-Aging Research Report
Sirona Biochem Corp. is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare’s newly published research report, “Novel Treatments for Age-Related Skin Problems.” The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market.
June 18, 2024
·
3 min read
Drug Development
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine(NEJM) has published results from a positive Phase 3 trial for Dupixent® (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE).
June 26, 2024
·
22 min read
BioCapital
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
Telomir Pharmaceuticals, Inc.(Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on Telomir-1 as a potential treatment for age-related conditions, today recapped its presentation of compelling pre-clinical data on Telomir-1 at a high-profile event hosted at the National Press Club in Washington, D.C., on April 15, 2024.
April 16, 2024
·
6 min read
Press Releases
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
August 20, 2024
·
5 min read
BioCapital
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
Telomir Pharmaceuticals, Inc. today announced that anti-aging expert and New York Times bestselling author Michael F. Roizen, MD, will present promising pre-clinical research on Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024.
April 2, 2024
·
5 min read
1 of 49,110
Next